58
Participants
Start Date
January 6, 2012
Primary Completion Date
June 30, 2014
Study Completion Date
January 22, 2015
Boceprevir
Boceprevir 200 mg capsules at 2400mg/day (800mg 3 times a day) from week 4 until week 48 or until liver transplant (can be performed from week 16)
Peg-Interferon α-2b or Peg-Interferon α-2a
Peg-Interferon α-2b by subcutaneous injection, 1.5µg/kg/week, from day 0 until week 48 or until liver transplantation, or Peg-Interferon α-2a by subcutaneous injection, 180 µg, once weekly, from day 0 until week 48 or until liver transplantation
Ribavirin
Ribavirin: capsules 200 mg (weight-based daily dose: \<65kg, 800 mg; 65-80kg, 1000mg; 81-105kg: 1200mg; \>105kg: 1400mg), from day 0 until week 48 or until liver transplantation or, Ribavirin: Tablet Oral, weight-based dose, 1000 mg for subjects weighing below 75 kg or 1200 mg for subjects weighing equal or over75 kg, once daily, from day 0 until week 48 or until liver transplantation
La Conception Hospital, Marseille
Haut-Lévêque Hospital, Bordeaux
Saint-Eloi Hospital, Montpellier
Trousseau Hospital, Tours
A Michallon Hospital, Grenoble
Nancy Hospital, Vandœuvre-lès-Nancy
La Pitié Salpétrière Hospital, Paris
Cochin Hospital, Paris
Beaujon Hospital, Clichy
Henri Mondor Hospital, Créteil
Claude Huriez hospital, Lille
La Croix-Rousse, Lyon
Archet Hospital, Nice
Staint Antoine Hospital, Paris
Pontchaillou Hospital, Rennes
Civil Hospital, Strasbourg
Purpan Hospital Médecine interne, Toulouse
Purpan Hospital, Toulouse
Paul Brousse Hospital, Villejuif
Merck Sharp & Dohme LLC
INDUSTRY
French National Agency for Research on AIDS and Viral Hepatitis
OTHER_GOV